- Germany considers going into second lockdown before Christmas
- Boris Johnson issues warning to prepare for no-deal Brexit
- US FDA advisory panel recommends approval of Pfizer Covid-19 vaccine
- US stimulus talks appear gridlocked
US stocks are trading lower as uncertainty regarding a new stimulus package and increasing number of COVID-19 fatalities overshadowed positive vaccine news. House Speaker Nancy Pelosi suggested stimulus negations could extend beyond Christmas, but said it would be preferable to pass a bill sooner. Both sides cannot find agreement on shielding companies from virus-related lawsuits, state and local stimulus, unemployment assistance and checks. On the pandemic front, a panel of experts formally recommended that the FDA authorize Pfizer and BioNTech’s coronavirus vaccine for emergency use. Also Canada became the second Western country to approve Pfizer's vaccine. Meanwhile US reported 2,768 COVID-19-related fatalities yesterday, a day after posting a record daily increase of 3,124, according Johns Hopkins University data.
US crude futures are trading 0.32% higher at $ 46.63 a barrel, while Brent contract fell 0.40% to $ 50.05. Elsewhere, gold futures rose 0.39% to $ 1,842.50 /oz, while silver is trading 0.27% near $ 24.00/oz.
GBPUSD – Sterling is the worst performing currency among majors as investors turned to safe-haven US dollar in the wake of surging COVID-19 infections, uncertainty over the timing of fiscal stimulus in the US, and the high probability for a no post-Brexit trade deal. Pair is currently testing strong support at 1.32 level which coincides with 200 SMA (red line). If sellers manage to close below that level then declines could deepen. However if buyers will manage to halt declines here, then upward impulse towards 1.3310 could be launched. Source: xStation5Chart of the day: JP225 (27.10.2025)
BREAKING: Ifo Index Slightly Above Expectations. DE40 limits jump from the session start
Morning wrap (27.10.2025)
Daily Summary: CPI down, Markets Up
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.